T2301

SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38α and p38β2 (IC50=50/100 nM) selectively and cell-permeably. SB 202190 has antitumor activity and also induces the differentiation of human embryonic stem cells into cardiomyocytes.

MNI 137 is a negative allosteric modulator of mGlu2. MNI 137 inhibits glutamate-induced calcium mobilization with IC50s of 8.3 and 12.6 nM for human and rat.

rapidly and efficiently releases glutamate

MRS1220, a selective and potent antagonist for the human A3 adenosine receptor (hA3AR) with a dissociation constant (Ki) of 0.59 nM, exhibits therapeutic promise for central nervous system disease research. It effectively diminishes glioblastoma tumor size and inhibits blood vessel formation in vivo.

antagonist for the human adenosine A3 receptor

competitive antagonist at P2Y1 receptors

MBL-IN-6 (Compound 6d) is a metal-β-lactamase (MBL) inhibitor with Ki values of 2.6 μM for NDM-1 and 0.08 μM for VIM-2. It acts synergistically with Imipenem against clinical isolates producing MBL, such as E. coli SI-M001, K. pneumoniae T2301, and S. marcescens SI-1591, with a MIC ranging from 2-64 μg/mL. MBL-IN-6 does not induce off-target effects and exhibits no inhibitory activity against ACE-1. This compound is useful for research on antibiotic resistance.